Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive efficacy and side effects
Contraception, Volume 34, No. 3, Year 1986
Notification
URL copied to clipboard!
Description
Two dosages of depot-medroxyprogesterone acetate (DMPA), 100mg and 150mg given every 90 days, were compared in two groups of women with regard to effectiveness, reported complaints and reasons for discontinuation. A total of 1216 women were recruited into a seven-centre, multinational, randomized clinical trial. Follow-up was for a period of one year and resulted in a total of 5507 woman-months of experience of 100mg DMPA and 5429 woman-months of experience of the 150mg dose. The study showed little difference in efficacy and side effects between the two treatment groups. Two pregnancies occurred in women receiving 100mg DMPA giving a Pearl Index of 0.44 per 100 woman-years. None occurred in the 150mg group. There was no difference in the overall continuation rates between the two groups at one year, being 59.3% in the 100mg group and 58.8% in the 150mg group. Except for discontinuation of method use for amenorrhea, the rates of all medical and non-medical reasons given for discontinuation were comparable between the two treatment groups. Women's perception of lack of bleeding was reported as amenorrhea and resulted in discontinuation rates at 12 months for amenorrhea of 7.2% for women receiving 100mg of DMPA and 12.5% for those receiving the 150mg dose. Three centres, Alexandria, Karachi and Szeged, made the major contributions to this difference. © 1986.
Authors & Co-Authors
Said, S.
Egypt, Alexandria
Faculty of Medicine
Omar, K.
Egypt, Alexandria
Faculty of Medicine
Koetsawang, Suporn
Thailand, Bangkok
Siriraj Hospital
Kiriwat, Orawan
Thailand, Bangkok
Siriraj Hospital
Srisatayapan, Yuwadee
Thailand, Bangkok
Siriraj Hospital
Kazi, A.
Pakistan, Karachi
National Research Institute of Fertility Control
Ajmal, F.
Pakistan, Karachi
National Research Institute of Fertility Control
Wynter, H. H.
Jamaica, Kingston
The University of the West Indies
Pretnar-Darovec, Alenka
Yugoslavia, Ljubljana
Hospital for Gynaecology and Obstetrics
Benitez, I.
Philippines, Manila
University of the Philippines Manila
de la Cruz, Julietta R.
Philippines, Manila
University of the Philippines Manila
Apelo, Ruben A.
Philippines, Manila
University of the Philippines Manila
Kovács, László G.
Hungary, Szeged
Szegedi Tudományegyetem Általános Orvostudományi Kar
Koloszár, Sándor
Hungary, Szeged
Szegedi Tudományegyetem Általános Orvostudományi Kar
Busca, B.
Unknown Affiliation
Hall, P. E.
Unknown Affiliation
Machin, David
Switzerland, Geneva
Organisation Mondiale de la Santé
United Kingdom, Southampton
University of Southampton
Statistics
Citations: 66
Authors: 17
Affiliations: 9
Identifiers
Doi:
10.1016/0010-7824(86)90004-1
ISSN:
00107824
Research Areas
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Cohort Study
Participants Gender
Female